BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Pan Tumor Rollover Study
- Conditions
- Cancer
- Interventions
- Drug: Regorafinib
- First Posted Date
- 2019-04-02
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1500
- Registration Number
- NCT03899155
- Locations
- 🇧🇪
Local Institution - 0232, Gent, Belgium
🇧🇪Local Institution - 0139, Jette, Belgium
🇧🇪Local Institution - 0261, Liege, Belgium
A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2021-03-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 44
- Registration Number
- NCT03890770
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇭🇺Szent Imre Egyetemi Oktatokorhaz, Budapest, Hungary
🇨🇿Pharmaceutical Research Associates CZ, s.r.o, Praha 7, Czechia
An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild to Severe Liver Damage
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2020-08-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT03890809
- Locations
- 🇭🇺
Kenezy Gyula Korhaz es Rendelointezet, Debrecen, Hungary
🇭🇺Clinical Research Unit Hungary, Miskolc, Hungary
🇨🇿Pharmaceutical Research Associates CZ, s.r.o, Praha 7, Czechia
A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy Participants
- Conditions
- Heart Failure
- Interventions
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2019-10-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 60
- Registration Number
- NCT03891108
- Locations
- 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States
Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)
- Conditions
- Active Psoriatic Arthritis
- Interventions
- Other: BMS-986165 PlaceboDrug: BMS-986165 Dose ADrug: BMS-986165 Dose BOther: Ustekinumab Placebo
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 203
- Registration Number
- NCT03881059
- Locations
- 🇺🇸
San Marcus Research Clinic, Miami Lakes, Florida, United States
🇺🇸Clinical Pharmacology Study Group, Worcester, Massachusetts, United States
🇺🇸Arthritis Associates, Hattiesburg, Mississippi, United States
Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 9
- Registration Number
- NCT03873415
- Locations
- 🇺🇸
Scintipharma, Lexington, Kentucky, United States
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
- Conditions
- Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 437
- Registration Number
- NCT03873402
- Locations
- 🇺🇸
Local Institution - 0013, Washington, District of Columbia, United States
🇺🇸Local Institution - 0053, Athens, Georgia, United States
🇺🇸Local Institution - 0066, Boston, Massachusetts, United States
A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies
- First Posted Date
- 2019-02-08
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 19
- Registration Number
- NCT03834662
- Locations
- 🇺🇸
START Midwest Clinic, Grand Rapids, Michigan, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Canada
Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis
- First Posted Date
- 2019-02-05
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 9
- Registration Number
- NCT03831438
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸Hospital of Special Surgery, New York, New York, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
A Study of Participants in Australia Who Have Non-small Cell Lung Cancer Being Treated With Nivolumab
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2019-01-15
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 503
- Registration Number
- NCT03804554
- Locations
- 🇦🇺
Local Institution, Heidelburg, Victoria, Australia